Colby Stong

Investigators compared the efficacy of Er:YAG plus long-pulsed Nd:YAG combination laser therapy with Er:YAG laser alone after 1 session in patients with recalcitrant warts.

Researchers evaluated the incidence, characteristics, and long-term outcomes of chronic immune-related adverse events resulting from adjuvant anti-PD-1 therapy in patients with resected high-risk melanoma.

Researchers examined the global burden of cardiovascular diseases attributable to particulate matter pollution from 1990 to 2019.

Researchers aimed to quantify the lifetime burden of Stevens-Johnson syndrome/ toxic epidermal necrolysis.

Researchers assessed the short- and long-term safety and efficacy of dupilumab in patients with bullous pemphigoid.

Researchers evaluated the efficacy and adverse events associated with modified 5-aminolevulinic acid photodynamic therapy vs isotretinoin therapy in patients with moderate to severe acne vulgaris.

Investigators evaluate the possible association between atopic dermatitis and alopecia areata.

Researchers assessed patients with chronic urticaria to determine the frequency and risk factors for CU exacerbations following COVID-19-vaccination.

Researchers sought to examine the safety and efficacy of ustekinumab and guselkumab as well as quality of life outcomes in patients with moderate-to-severe plaque psoriasis.

Investigators compare the risk for infectious complications among patients with psoriasis receiving IL-17, IL-23, or TNF inhibitors.

Researchers evaluate the impact of telehealth conference vs in-person visits on apremilast adherence and persistence in patients with psoriasis or psoriatic arthritis.

Investigators assessed the association of vitiligo with autoimmune and inflammatory diseases.

Researchers assessed drug survival rates of dupilumab up to 2 years in adults with moderate to severe atopic dermatitis and analyzed predictive factors affecting treatment persistence.

Researchers evaluated clinical, functional, and quality-of-life effects of ixekizumab in patients with moderate to severe psoriasis.

Investigators evaluated the association between upadacitinib use and treatment-emergent acne.

Researchers sought to determine the safety and efficacy of upadacitinib in patients with moderate to severe atopic dermatitis who were unresponsive to or intolerant of conventional or biologic systemic treatments.

A meta-analysis estimated the PaO2 decrease associated with each kilometer of vertical gain in healthy adults traveling to high altitude regions.

Researchers assessed the safety and efficacy of an antibiotic-free, fixed-dose combination of microencapsulated tretinoin and BPO cream for acne vulgaris.

Investigators evaluated clinical features, disease-specific biomarkers, predictive factors, and management of paradoxical reactions, especially paradoxical psoriasis.

Researchers evaluated the effectiveness of a smoking cessation program in Black adults that combined multiple pharmacotherapy adaptations with nicotine patch use.

Researchers sought to evaluate meaningful improvements in clinical signs, symptoms, and quality of life with topical corticosteroids plus either dupilumab or placebo in children with severe atopic dermatitis.

Researchers sought to examine the epidemiology of chlorhexidine allergy and characterize positive patch test reactions.

Researchers conducted a systematic review and meta-analysis of patients who received isavuconazole and other antifungal agents to assess the efficacy and safety of isavuconazole for invasive fungal infections.

Investigators reviewed 39 lesser-known adverse events of interest associated with dupilumab.

Researchers evaluate the safety and efficacy of 30 mg upadacitinib and analyze outcomes of switching to upadacitinib after 24 weeks of dupilumab.

Researchers evaluated the cutaneous carcinogenic risk associated with UVB phototherapy in patients with atopic dermatitis.

Investigators examined whether the use of topical calcineurin inhibitors is associated with a higher risk for any cancer compared with the use of topical corticosteroid among patients with atopic dermatitis.

An interim analysis of GUIDE assessed the impact of psoriasis duration on clinical response, including the proportion of super-responders, after 28 weeks of guselkumab.

Researchers assess the real-life incidence of bleeding complications linked to the use of direct oral anticoagulants in the setting of dermatologic surgery.

Investigators analyzed targeted therapies for nail psoriasis, with a focus on newer agents such as brodalumab, risankizumab, and tildrakizumab.